Trends of antibiotic consumption in korea according to national reimbursement data (2008-2012) a population-based epidemiologic study

Medicine (United States)

Volumn 94, Issue 46, 2015, Pages e2100-

  Yoon, Young Kyung ^a,b   Park, Gi Chan ^c   An, Hyonggin ^c   Chun, Byung Chul ^d   Sohn, Jang Wook ^a,b   Kim, Min Ja ^a,b  

^a College of Medicine   (South Korea)

^b Institute of Emerging Infectious Diseases   (South Korea)

^c Department of Biostatistics ^*  (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; LINEZOLID; MACROLIDE; METRONIDAZOLE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DESCRIPTIVE RESEARCH; DRUG ABUSE; DRUG MISUSE; DRUG USE; EPIDEMIOLOGY; GROUPS BY AGE; HEALTH CARE POLICY; INFLUENZA; MULTIDRUG RESISTANCE; NATIONAL HEALTH INSURANCE; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PRIVATE HOSPITAL; PROSPECTIVE STUDY; REIMBURSEMENT; RETROSPECTIVE STUDY; SEASONAL VARIATION; SEX DIFFERENCE; SOUTH KOREA; SYSTEMIC THERAPY; TERTIARY CARE CENTER; TIME SERIES ANALYSIS; ADOLESCENT; ADULT; AGED; CHILD; CLINICAL PRACTICE; DRUG UTILIZATION; FEMALE; HUMAN; INAPPROPRIATE PRESCRIBING; INFANT; MALE; MIDDLE AGED; NEWBORN; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRESCHOOL CHILD; PREVENTION AND CONTROL; PROTOCOL COMPLIANCE; PUBLIC HEALTH; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEALTH POLICY; HUMANS; INAPPROPRIATE PRESCRIBING; INFANT; INFANT, NEWBORN; INSURANCE, HEALTH, REIMBURSEMENT; LINEAR MODELS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PERIOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84948702416     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002100     Document Type: Article

References (38)

1. Spellberg B, Blaser M, Guidos RJ, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52:S397-S428.
2. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008;46:S360-S367.
3. Yu WL, Chuang YC, Walther-Rasmussen J. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect. 2006;39:264-277.
4. Pogue JM, Mann T, Barber KE, et al. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther. 2013;11:383-393.
5. Temkin E, Adler A, Lerner A, et al. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci. 2014;1323:22-42.
6. Filice GA, Nyman JA, Lexau C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31: 365-373.
7. Roberts R, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175-1184.
8. ECDC/EMEA Joint Technical Report. The bacterial challenge: time to react. 2009. EMEA/576176/2009. http://ecdc.europa.eu/en/publications/Publications/0909-TER-The-Bacterial-Challenge-Time-to-React. pdf. Accessed June 23, 2015.
9. Angebault C, Andremont A. Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design. Eur J Clin Microbiol Infect Dis. 2013;32:581-595.
10. Gravatt LA, Pakyz AL. Challenges in measuring antibiotic consumption. Curr Infect Dis Rep. 2013;15:559-563.
11. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2 Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999;29:245-252.
12. Bager F. DANMAP: monitoring antimicrobial resistance in Denmark. Int J Antimicrob Agents. 2000;14:271-274.
13. Mölstad S, Erntell M, Hanberger H, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis. 2008;8:125-132.
14. Zarb P, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): value of a point-prevalence survey of antimicrobial use across Europe. Drugs. 2011;71:745-755.
15. Yong D, Shin HB, Kim Y, et al. Increase in the prevalence of carbapenem-resistant Acinetobacter isolates and ampicillin-resistant non-typhoidal Salmonella species in Korea: A KONSAR study conducted in 2011. Infect Chemother. 2014;46:84-93.
16. National Health Insurance Service and Health Insurance Review and Assessment, Service, 2013 National Health Insurance Statistical, Yearbook, 2014. http://www.129.go.kr/news/news02-view.jsp?n8076. Accessed June 23, 2015.
17. Kim SY, Kim HE, Back MS, et al. The effect of public report on antibiotics prescribing rate. Kor J Clin Parm. 2010;20:242-247.
18. Health Insurance Review and Assessment Service. 2009 Report of prophylactic antibiotics for preventing surgical infection. 2009. http://www.hira.or.kr/ebook/af1fb128-3502-40bf-b45c-60cd1dfddfac/110-page-img/extra/110.pdf. Accessed June 23, 2015.
19. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc-ddd-index/. Accessed June 23, 2015.
20. Statistics Korea. Korean Statistical Information Service. http://kosis.kr/statisticsList/statisticsList-01List.jsp?vwcdMT-ZTITLE&parm TabIdM-01-01#SubCont. Accessed June 23, 2015.
21. Versporten A, Bolokhovets G, Ghazaryan L, et al. Antibiotic use in Eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe. Lancet Infect Dis. 2014;14:381-387.
22. European Centre for Disease Prevention and Control. Summary of the latest data on antibiotic consumption in the European Union. European Antibiotic Awareness Day. November, 2012. http://www.ecdc.europa.eu/en/eaad/documents/eaad-2011-summary-antimicrobial-consumption-data.pdf. Accessed June 24, 2015.
23. European Centre for Disease Prevention and Control. Country overview of antimicrobial consumption. http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance/esac-net-database/Pages/overview-country-consumption.aspx. Accessed June 24, 2015.
24. Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. 2004;48:2101-2107.
25. Hong KB, Choi EH, Lee HJ, et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Emerg Infect Dis. 2013;19:1281-1284.
26. Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012;56:1418-1426.
27. Korea Centers for Disease Control. 2011 Case definitions for National Notifiable Infectious Diseases. http://www.cdc.go.kr/CDC/contents/CdcKrContentView.jsp?cid21153&menuIdsHOME001-MNU1132-MNU1138-MNU1065. Accessed June 23, 2015.
28. Yoon YK, Yang KS, Lee SE, et al. Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenemuse stewardship. PLoS ONE. 2014;9:e99101.
29. Lee K, Yong D, Jeong SH, et al. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J. 2011;52:879-891.
30. The Alliance for the Prudent Use of Antibiotics. Nightmare bacteria and the worldwide threat to carbapenem. APUA Clinical Newsletter. 2013;31:1-28. http://www.tufts.edu/med/apua/news/newsletter.shtml. Accessed June 23, 2015.
31. Vander Stichele RH, Elseviers MM, Ferech M, et al., European Surveillance of Antibiotic Consumption (ESAC) Project Group. Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997-2002). J Antimicrob Chemother. 2006;58:159-167.
32. Kim YJ, Chun HJ, Lee JW, et al. The changing patterns of antibiotics usage in Korea during 1981-2008. Infect Chemother. 2012;44:411-418.
33. Gonzales R, Anderer T, McCulloch CE, et al. A cluster randomized trial of decision support strategies for reducing antibiotic use in acute bronchitis. JAMA Intern Med. 2013;173:267-273.
34. Bao L, Peng R, Wang Y, et al. Significant reduction of antibiotic consumption and patients' costs after an action plan in China, 2010-2014. PLoS ONE. 2015;10:e0118868.
35. Wang J, Wang P, Wang X, et al. Use and prescription of antibiotics in primary health care settings in China. JAMA Intern Med. 2014;174:1914-1920.
36. Chun DS, Cheong KH. Analysis about effects of public information: the proportion of antibiotic prescription for upper respiratory tract infection in Seoul. Korean Policy Stud Rev. 2011;20:109-142.
37. Polk RE, Fox C, Mahoney A, et al. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44:664-670.
38. Muller A, Monnet DL, Talon D, et al. Discrepancies between prescribed daily doses and WHO defined daily doses of antibacterials at a university hospital. Br J Clin Pharmacol. 2006;61:585-591.